Clinical Trials
Epeius Biotechnologies has expanded it's ongoing clinical trials for Rexin-G™ in the USA to include breast cancer and all types of sarcomas that are refractory to standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA has granted Orphan Drug Status for Rexin-G™ for treating pancreatic cancer while the Philippine BFAD has granted Expanded Access for Rexin-G™ for treating all chemo-resistant solid tumors. Rexin-G™ is a tumor-targeted nanomedicine - a targeted gene delivery vehicle that seeks out and destroys both primary tumors and metastatic cancer that has spread throughout the body. Delivered by simple intravenous infusion, Rexin-G has demonstrated unprecedented single-agent-efficacy against a broad spectrum of tumor types where chemotherapeutics and many other biologics have failed.
Clinical Trials Using Rexin-G®
Epeius is currently conducting a number of clinical trials in the U.S. and abroad for Rexin-G®, as therapeutic intervention for metastatic or locally advanced cancers. Based on profound evidence of single agent efficacy in a broad spectrum of chemo-resistant tumors, Rexin-G® has been approved for use in "all solid tumors" under an Expanded Access Program in The Republic of the Philippines. Consequently, many patients from around the world are currently being treated by top oncologists in Manila, and a number of provisions have been made to facilitate this medical opportunity for patients and their families.
Following the completion of several years of safety studies at the Mayo Clinic, Epeius has undertaken an ambitious program to bring Rexin-G® to cancer patients in the United States. In the summer of 2007, Epeius opened three Advanced Phase I/II Clinical trials:
1. Sarcomas of all types (failed chemotherapy)
2. Breast Cancer (failed std. chemotherapy)
3. Pancreatic Cancer (failed gemcitabine)
These new clinical trials of Rexin-G® will initially be centered in San Marino, California, where Epeius Biotechnologies Corp. has its headquarters, and in Santa Monica, where Dr. Sant Chawla, M.D., a renowned expert on malignant sarcomas will serve as Principal Investigator (PI). With the global demand for Rexin-G increasing, Epeius is actively engaged in the development of additional trials and additional treatment centers in the United States and around the world.
For further up-to-date information concerning the clinical trials, treatment options, and/or eligibility requirements patients may contact our medical director, Dr. Erlinda M.Gordon, directly: egordon@epeiusbiotech.com .
